Skip to main content
Erschienen in: Indian Journal of Gastroenterology 6/2016

15.11.2016 | Original Article

Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes

verfasst von: Samir R. Shah, P. N. Rao, Shiv K. Sarin, Abhijit Chowdhury, Shobna Bhatia, Rajesh Dharamsi, B. D. Goswami, Dharmesh Kapoor, Rosang Luaia, Rajiv Mehta, Shrikant Mukewar, V. G. Mohan Prasad, Ramesh Roop Rai, Sanjiv Saigal, Devendra Singh, Nirupama Trehanpati, Sandra Chen, Anuj Gaggar, Steven J. Knox, G. Mani Subramanian, Shivaram Prasad Singh, Ajit Sood, Joy Varghese, Raj Vigna Venugopal

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

Although chronic hepatitis C virus (HCV) infection affects millions of people in India, few studies have assessed host, viral, and disease characteristics of chronically infected patients at national and regional levels. Such information is critical to support large scale screening and treatment initiatives for chronic HCV infection in India.

Methods

Patients with known chronic HCV infection making routine or for-cause visits to the participating study centers were enrolled in this observational study. Patients attended a single outpatient visit during which demographics and medical history were collected, a physical examination was performed, and blood and urine samples were collected for laboratory assessments. Samples were analyzed to determine HCV genotypes and subtypes, and genotypes of interferon lambda 3 (IFNL3) single nucleotide polymorphism. No therapeutic interventions were administered.

Results

We enrolled 500 patients at 19 centers, categorized into four geographic regions (North, South, East, and West). All patients self-identified as Indian, and most (66 %) were male. Genotype 3 was the most common genotype overall (54 %); however, its prevalence varied greatly by region, ranging from 34 % in the South to 69 % in the East. Genotypes 1 (24 %) and 4 (6 %) were the next most common, and HCV genotype could not be determined for 16 % of patients.

Conclusions

This prospective survey suggests that demographics, viral, and host factors in patients with chronic HCV infection are highly variable in India and pose significant challenges for the implementation of broad-scale screening and treatment initiatives.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80.CrossRefPubMed Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80.CrossRefPubMed
2.
Zurück zum Zitat Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed
3.
Zurück zum Zitat Saravanan S, Velu V, Kumarasamy N, et al. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis. 2008;12:513–8.CrossRefPubMed Saravanan S, Velu V, Kumarasamy N, et al. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis. 2008;12:513–8.CrossRefPubMed
4.
Zurück zum Zitat Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J Viral Hepatol. 2015;22:26–45.CrossRef Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J Viral Hepatol. 2015;22:26–45.CrossRef
5.
Zurück zum Zitat Tamayo A, Shah SR, Bhatia S, et al. Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India. Hepatol Int. 2016;10:988-995. Tamayo A, Shah SR, Bhatia S, et al. Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India. Hepatol Int. 2016;10:988-995.
6.
Zurück zum Zitat Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed
7.
Zurück zum Zitat Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding regions. Liver Int. 2012;32:339–45.CrossRefPubMed Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding regions. Liver Int. 2012;32:339–45.CrossRefPubMed
8.
Zurück zum Zitat Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed
9.
Zurück zum Zitat Kaur H, Singh P, Pannu HS, Sood A, Jain NP, Bhoday HS. To study the prevalence of impaired glucose tolerance in patients with hepatitis C virus related chronic liver disease. J Clin Diagn Res. 2015;9:OC16–20.PubMedPubMedCentral Kaur H, Singh P, Pannu HS, Sood A, Jain NP, Bhoday HS. To study the prevalence of impaired glucose tolerance in patients with hepatitis C virus related chronic liver disease. J Clin Diagn Res. 2015;9:OC16–20.PubMedPubMedCentral
10.
Zurück zum Zitat Pastore F, Martocchia A, Stefanelli M, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol. 2016;8:83–91.CrossRefPubMedPubMedCentral Pastore F, Martocchia A, Stefanelli M, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol. 2016;8:83–91.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.CrossRefPubMed Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.CrossRefPubMed
12.
Zurück zum Zitat Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297–305.CrossRefPubMed Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297–305.CrossRefPubMed
Metadaten
Titel
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes
verfasst von
Samir R. Shah
P. N. Rao
Shiv K. Sarin
Abhijit Chowdhury
Shobna Bhatia
Rajesh Dharamsi
B. D. Goswami
Dharmesh Kapoor
Rosang Luaia
Rajiv Mehta
Shrikant Mukewar
V. G. Mohan Prasad
Ramesh Roop Rai
Sanjiv Saigal
Devendra Singh
Nirupama Trehanpati
Sandra Chen
Anuj Gaggar
Steven J. Knox
G. Mani Subramanian
Shivaram Prasad Singh
Ajit Sood
Joy Varghese
Raj Vigna Venugopal
Publikationsdatum
15.11.2016
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 6/2016
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-016-0709-1

Weitere Artikel der Ausgabe 6/2016

Indian Journal of Gastroenterology 6/2016 Zur Ausgabe

Acknowledgements

Acknowledgements

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.